25 Nov 2022 07:00
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Receipt of deferred consideration
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.
Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group PLC | www.omegadiagnostics.com | |
Jag Grewal, Chief Executive | via Walbrook PR | |
Chris Lea, Chief Financial Officer | ||
finnCap Ltd | Tel: 020 7220 0500 | |
Geoff Nash/Edward Whiley (Corporate Finance) | ||
Alice Lane/ Harriet Ward (ECM) | ||
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com | |
Paul McManus / Sam Allen | Mob: 07980 541 893 / Mob: 07502 558 258 | |
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.
www.omegadx.com
ODX.L (ODX)